Maintaining Outperform: A Nonrecurring-Heavy Beat-and-Raise — But the Recovery Got Confirmed AND De-Risked, With the Medicaid Trough Holding and the 2027 MA Rate Firming, Against a Contained $935M CMS Overhang
Key Takeaways
- Read past the headline beat-and-raise — it's low quality. Adjusted EPS of $12.58 cleared the ~$10.80 Street number by ~16%, and the FY2026 guide rose $1.25 to at least $26.75 — but ~$1.00 of both the beat and the raise is nonrecurring net-investment-income gains, and another ~$0.15 is ACA bronze-mix timing that reverses in H2. The clean, underlying raise to the 2026 earnings baseline was just $0.25, to $25.75.
- The confirmation, however, is high quality — and de-risking. The two things that could have broken the Q4 upgrade both went the right way: the Medicaid trough is holding (−1.75% operating margin reaffirmed, Q1 slightly favorable), and CMS firmed the 2027 MA rate ("addressed a portion of the funding challenges" versus the flat advance notice) — directly retiring the single biggest risk we flagged when we upgraded.
- A new but contained overhang: the $935M CMS accrual. ELV booked a $935M charge (excluded from adjusted EPS; GAAP EPS was $8.00) for a historical risk-adjustment-data matter flagged by CMS in February. Management has until July 31 to satisfy CMS's compliance steps and expects sanctions will not take effect; it stresses the matter concerns historical periods, not current practices, and does not change the outlook. We treat it as a one-time cash/headline risk, not an earnings-power impairment — but it is a real watch item.
- The operating story is broadening. ACA effectuation is tracking to ~1.2M by Q2 (ahead of plan) with a favorable bronze shift and morbidity as-priced; commercial/ASO has a near-record 2027 pipeline and ~99% national-account retention; MA is on track to ≥2%; and CareBridge is posting hard proof points (−20% readmissions, >10% post-acute savings). The diversified-recovery bridge has more legs than it did two quarters ago.
- Rating: Maintaining Outperform. The stock faded a +3% open to close flat after a +13% trailing-month run, so the easy recovery-trade money is made — but at ~12x the raised guide (~12.7x the clean $25.75 baseline), with the trough holding, the 2027 MA rate de-risked, and a reaffirmed ≥12% 2027 algorithm, the risk/reward still favors ownership. The CMS accrual and the nonrecurring-heavy beat temper our enthusiasm without changing the thesis.
Results vs. Consensus
Q1 2026 Scorecard
| Metric | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Operating Revenue | $49.5B | ~$48.8B | Beat | +~1.4% |
| Adjusted EPS (reported) | $12.58 | ~$10.80 | Beat | +~16% |
| Adjusted EPS (ex ~$1 nonrecurring) | ~$11.58 | ~$10.80 | Beat | +~7% |
| GAAP Diluted EPS | $8.00 | n/a | — | after $935M CMS + $129M charges |
| Consolidated Benefit Expense Ratio (MLR) | 86.8% | ~87.3% | Beat (lower) | −~50bps |
| Adj. Operating Expense Ratio | 10.5% | ~10.6% | In line/beat | −20bps YoY |
| Medical Members | 45.4M | ~45.3M | In line/beat | +~200K vs YE |
| FY2026 Adj. EPS Guide | ≥$26.75 | ~$26 (Street) | Raised | +$1.25 (mostly nonrecurring) |
Year-Over-Year Comparisons
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Operating Revenue | $49.5B | $48.8B | +1.5% |
| Adjusted EPS | $12.58 | $11.97 | +5.1% |
| Benefit Expense Ratio | 86.8% | 86.4% | +40bps |
| Adj. Operating Expense Ratio | 10.5% | 10.7% | −20bps |
| Medical Membership | 45.4M | 45.8M | −0.9% |
The +5.1% YoY adjusted-EPS growth is the first positive YoY print in over a year — but ~$1 of it is the nonrecurring investment gain. Ex-that, clean adjusted EPS was roughly flat YoY (~$11.58 vs $11.97), consistent with 2026 being a managed trough. Revenue growth has decelerated sharply to +1.5% as deliberate membership exits offset premium-yield gains — the expected signature of a repositioning year.
Quarter-Over-Quarter Comparisons
| Metric | Q1 2026 | Q4 2025 | Change |
|---|---|---|---|
| Operating Revenue | $49.5B | $49.3B | +0.4% |
| Adjusted EPS | $12.58 | $3.33 | +278% (seasonal) |
| Benefit Expense Ratio | 86.8% | 93.5% | −670bps (seasonal) |
| Days in Claims Payable | 46.6 | 41.3 | +5.3 (seasonal/mix) |
Q1 is structurally the highest-EPS, lowest-MLR quarter for managed care (deductibles reset, claims build slowly), so the massive QoQ EPS jump and 670bps MLR drop are pure seasonality — management guided Q1 to ~43% of the full year and Q2 to ~23%. The 5.3-day DCP build is seasonal/mix, not a reserve-approach change (per CFO).
Quality of Beat/Miss
- EPS: Mixed quality. Of the ~$1.45 beat versus the company's own initial Q1 plan, ~$1.00 was nonrecurring net-investment-income valuation gains and ~$0.15 was ACA bronze-plan timing (cost deferred to H2) — leaving ~$0.30 of genuine underlying business favorability (~$0.10 of which was a milder flu season). The clean operating beat is real but modest.
- Margins: The 86.8% benefit ratio came in ~50bps below expectations on favorable claims experience plus early traction from cost-management actions — the higher-quality part of the print, because it reflects the self-help levers the recovery thesis depends on rather than one-time items.
- Guidance: The $1.25 raise is ~80% nonrecurring. The honest, modelable improvement is the $0.25 lift to the clean baseline ($25.75) — small, but a positive revision in a name that delivered only negative revisions for two years.
The Guidance Raise, Decomposed
| Component of the $1.25 FY2026 raise | Amount | Quality | In the 2027 baseline? |
|---|---|---|---|
| Nonrecurring net-investment-income gains | ~$1.00 | One-time | Excluded |
| Underlying non-seasonal business favorability | ~$0.25 | Durable | Included ($25.75 baseline) |
| FY2026 adj. EPS guide | ≥$26.75 | — | Baseline = $25.75 |
The structure here is the whole story. Management raised the headline to at least $26.75 but was explicit that the $1 nonrecurring "should clearly be excluded from the 2026 earnings baseline," so the figure that anchors the 2027 ≥12% growth commitment moved up only $0.25, to $25.75. That is a deliberately conservative posture — taking the headline credit for the windfall while refusing to let it inflate the base off which next year's growth is measured. After two years of over-promising, this is precisely the under-promise discipline the franchise needed to demonstrate.
2027 math: ≥12% off a $25.75 base implies ~$28.85+ in 2027. At the $328.20 close, the stock trades ~12x that forward number — a multiple that still embeds skepticism about whether the recovery compounds.
The $935M CMS Risk-Adjustment Accrual
Assessment: A genuinely new overhang, and one a disciplined analyst cannot wave away — a near-$1B charge tied to risk-adjustment integrity is exactly the kind of item that can metastasize in managed care. But three things keep it contained in our framework: (1) it is excluded from adjusted earnings and the ongoing earnings power; (2) management sized it, accrued for it, and has a defined CMS process with a July 31 deadline and an expectation of no sanctions; and (3) it relates to historical interpretation of risk-adjustment policy, not current governance. We model it as a one-time cash outflow risk, not a recurring drag — while flagging the July 31 resolution as a discrete catalyst/risk to monitor. If the resolution slips or the exposure grows materially, it would pressure the rating.
Segment Performance
| Segment | Q1 Read | FY2026 Setup | Recovery Signal |
|---|---|---|---|
| Medicaid | Slightly favorable | −1.75% margin (trough) reaffirmed | Trough holding; self-help showing |
| Medicare Advantage | Stronger than expected | On track to ≥2%; 2027 final rate firmed | Biggest Q4 risk de-risked |
| Individual ACA | Bronze tailwind | ~1.2M by Q2 (ahead); morbidity as-priced | Repricing working |
| Commercial Group | As planned | Near-record 2027 pipeline; ~99% retention | Demand for integrated model |
| Carelon (Services + Rx) | Gain down modestly YoY | Affiliated headwind; mid-5% Rx margin | Risk-based scaling; CareBridge proof points |
Medicaid — the trough is behaving
Medicaid came in slightly favorable to plan, with the full-year −1.75% operating-margin outlook reaffirmed and management reiterating 2026 as the trough. Q1 Medicaid rates (about a third of the book resets in January, through April) landed in line at roughly mid-single-digit — still below trend, but the gap is being worked with states on both rates and program/benefit design. Early traction from cost-management actions (behavioral health, specialty pharmacy, ABA oversight, substance-use predictive analytics) is beginning to show through.
"Certainly, on a sequential basis, we did see an expected deterioration in the first quarter, meaning coming in exactly as we anticipated. And so for the full year, we're continuing to be very comfortable with our guide of minus 1.75% operating margin." — Mark Kaye, CFO
Assessment: "Exactly as anticipated" is the most valuable phrase a managed-care CFO can deliver on the segment that broke the franchise for two years. A trough that behaves on plan in Q1 is what converts the −1.75% from a forecast into a track record. The rate-to-trend gap persists, but it is closing in the predicted direction.
Medicare Advantage — the 2027 rate de-risks the bridge
MA results were stronger than anticipated on the 2026 portfolio actions (exits, repositioning), keeping the ≥2% margin target on track. The pivotal new datapoint: CMS's final 2027 MA rate addressed a portion of the funding shortfall that the flat February advance notice had implied — the exact risk we flagged when upgrading at Q4.
"We were also encouraged to see CMS address a portion of the funding challenges in the final rates for 2027. As we prepare for bid submissions, we will remain disciplined." — Gail Boudreaux, CEO
Assessment: This is the single most important sentence in the print for the multi-year thesis. A firmer 2027 rate directly supports the MA leg of the ≥12% 2027 bridge — the leg most exposed to the flat advance notice. It does not eliminate MA-rate risk (bids are still disciplined into a tight environment), but it materially de-risks the recovery relative to where the debate stood in January.
Individual ACA — the repricing is working
ACA membership grew sequentially and is tracking to ~1.2M by end-Q2, ahead of the initial outlook, helped by 2025 expansion states and a pronounced consumer shift to bronze plans (more affordable net-of-subsidy as benchmark silver premiums rose). Critically, early morbidity signals — renewing paid-status members showing moderately higher prior claims than the cancel/nonpayment cohorts — confirm the higher residual acuity ELV priced for. Management held the conservative ≥900K full-year outlook despite the stronger Q1.
"That dynamic... is tracking consistent with or even better than how we price the business in 2026. And so... I feel very good about our membership mix, and I feel very encouraged by that shift towards bronze." — Mark Kaye, CFO
Assessment: ACA has flipped from 2025's primary wound to a 2026 self-help win. The bronze mix is a margin positive, and morbidity tracking as-priced removes the "another adverse-selection surprise" tail. Holding ≥900K while tracking to 1.2M is exactly the conservatism the guide needs — it preserves room to beat and reflects genuine uncertainty about H2 effectuation.
Carelon — the affiliated drag, as scripted
Carelon's Q1 operating gain declined modestly YoY on lower affiliated health-plan membership and continued risk-based investment, partly offset by specialty-pharmacy and CareBridge improvement. CarelonRx margin was in line at the guided mid-5% range. Management continues to scale risk-based programs (oncology, post-acute, behavioral) along the commercial→Medicare→Medicaid path, using the affiliated book as a proving ground.
"One of the real advantages in Carelon here is that we can use our affiliated health plan membership as a proving ground to launch and scale capabilities quickly... we started our risk-based oncology solution in commercial. We expanded it into Medicare. And then we plan to move it into Medicaid in the latter half of this year." — Mark Kaye, CFO
Assessment: The affiliated-membership headwind is exactly as guided at Q4 and is transitory — it unwinds as the health-plan base stabilizes into 2027. The risk-based scaling is the structural growth engine; CareBridge's hard proof points (−20% readmissions, >10% post-acute savings) validate that the model bends cost, not just shifts it. Carelon remains the 2027 re-acceleration story.
Key KPIs
| KPI | Q1 2026 | Q1 2025 | Trend | Read |
|---|---|---|---|---|
| Medical members | 45.4M | 45.8M | ↓ YoY / ↑ vs YE | Commercial fee + ACA up; MA/EGR/Medicaid down |
| Benefit expense ratio | 86.8% | 86.4% | ↑ slightly | Better than assumed; self-help showing |
| Adj. operating expense ratio | 10.5% | 10.7% | ↓ | Discipline + AI despite investment |
| Days in claims payable | 46.6 | ~45 | ↑ (seasonal/mix) | No reserve-approach change; PYD ~$250M |
| Operating cash flow | $4.3B | ~$2.1B | ↑ | FY ≥$5.5B (incl. potential CMS payments) |
| Buyback | $1.1B (3.7M sh @ ~$300) | ~$380M | ↑ | Accretive at washed-out price |
Key Topics & Management Commentary
Overall Management Tone: Confident and execution-focused, with a notable shift from defending the trough to demonstrating early traction — management repeatedly anchored the narrative to "actions showing through in the results" rather than promises about the future. The tone on the new CMS matter was measured and process-oriented (sized, accrued, defined timeline, expectation of no sanctions) rather than defensive, and on the 2027 MA rate it was pointedly relieved. The one place management stayed deliberately conservative was guidance: it took the headline credit for the nonrecurring gain but refused to let it inflate the 2027 baseline — a posture calibrated to rebuild credibility.
1. The Beat Decomposed — and the $0.25 Clean Raise
Management was unusually transparent in parsing the quarter: ~$0.45 of core outperformance (~$0.30 underlying, ~$0.15 ACA timing) plus ~$1.00 of nonrecurring investment income, with the latter explicitly carved out of the 2026 baseline.
"Of that increased [$1.25], $0.25 reflects that portion of the underlying nonseasonal business favorability we saw in the quarter. And of course, the remaining $1 was a nonrecurring item... that dollar should clearly be excluded from the 2026 earnings baseline." — Mark Kaye, CFO
Assessment: The transparency is the point. Management could have let the $1.25 raise read as broad-based strength; instead it volunteered the $0.25/$1.00 split and protected the baseline. That is the behavior of a team optimizing for multi-year credibility over a one-quarter headline — and it makes the modest $25.75 baseline more trustworthy.
2. The Medicaid Trough Holds
The −1.75% full-year Medicaid margin was reaffirmed with Q1 slightly favorable, and management held the trough framing firmly. Rates (~1/3 of book through April) came in at mid-single-digit, in line but still below trend; the gap is being closed via both rate advocacy and self-help (benefit design, payment integrity, site-of-care).
"This is aligning similar to what we put in our guidance. And we do, as we've shared before... this is the trough year. And we continue to believe that given what we're seeing in the business." — Gail Boudreaux, CEO
Assessment: A trough that lands on plan in its first quarter is the proof the recovery thesis needed. The rate-to-trend gap persists into July rate cycles, but the trajectory is intact and the self-help levers are additive to whatever rates deliver.
3. The 2027 MA Rate Firms — De-Risking the Recovery
CMS's final 2027 MA rate addressed part of the funding gap the flat advance notice implied — the most important external development for the multi-year thesis, given how much the ≥12% 2027 bridge leans on MA margin recovery.
"We were also encouraged to see CMS address a portion of the funding challenges in the final rates for 2027." — Gail Boudreaux, CEO
Assessment: This converts the biggest open risk from our Q4 upgrade into a partial positive. It does not make MA easy — the environment is still tight and bids stay disciplined — but it removes the tail scenario where a flat rate breaks the 2027 algorithm on arrival.
4. The $935M CMS Accrual — Sized and Process-Defined
Management framed the accrual as a best estimate of identified historical exposure, with a CMS-prescribed compliance process and a July 31 deadline after which it expects no sanctions, repeatedly stressing the matter does not touch current practices or the outlook.
"Based on the steps that CMS has prescribed and the current timeline... we believe and expect that if we complete those steps that the sanctions will not go into effect." — Gail Boudreaux, CEO
Assessment: Sized, accrued, and bounded by a defined process is the best an investor can ask of a new regulatory item at first disclosure. The residual risk is execution against the July 31 deadline and the possibility the exposure grows — a discrete catalyst we will track, not an earnings-power impairment.
5. ACA: Bronze Shift and Morbidity As-Priced
The pronounced shift to bronze plans is a net positive (more affordable net-of-subsidy), effectuation is ahead of plan (~1.2M by Q2), and early morbidity indicators confirm the higher residual acuity ELV priced for — removing the adverse-selection tail that dogged 2025.
"One really early indicator... prior claims experience for renewing members in paid status running moderately higher than for the cancel or nonpayment cohorts... that is tracking consistent with or even better than how we price the business in 2026." — Mark Kaye, CFO
Assessment: ACA self-help is working. The conservatism of holding ≥900K while tracking to 1.2M preserves beat room and acknowledges genuine H2 effectuation uncertainty. The bronze MLR pattern (cost deferred to H2) is the one thing to watch — Q1 strength partly reverses later in the year, which is already in the guide.
6. Commercial & ASO: Near-Record 2027 Pipeline
Commercial developed as planned with disciplined pricing, and the forward selling season is a clear strength: a near-record 2027 pipeline (~2M members in queue), ~99.3% national-account retention, strong CarelonRx pull-through, and continued single-carrier consolidation wins.
"The renewal numbers that we've seen in our national business are nearly 100%. It's like 99.3%... these are organizations that don't move very often. They like what they're getting." — Morgan Kendrick, President, Commercial Health Benefits
Assessment: Commercial/ASO is the quiet ballast of the 2027 bridge — fee-based, capital-light, sticky, and growing. A near-record pipeline into 2027 adds a non-MA, non-Medicaid leg to the recovery that does not depend on rate cycles.
7. AI and the >$1B Investment
Management detailed its >$1B digital/AI investment as embedded-at-scale rather than experimental: 22M commercial members on the AI virtual assistant, Sydney provider-matching (>20% of members), HealthOS reducing prior-auth denials ~70%, and 60,000+ associates with AI access — all targeted at lowering cost and administrative complexity.
"We're investing more than $1 billion in digital and AI-enabled capabilities... we're not approaching AI as a separate technology element or experimentation. We're looking at things that will scale and support those absolute core things of our business." — Gail Boudreaux, CEO
Assessment: The AI spend is part of the ~$1 of 2026 investment drag, and its payoff is the source of the 2027 operating leverage in the ≥12% bridge. The proof points (denial reduction, effort scores) are concrete enough to credit as a real efficiency lever, not just narrative.
8. The 2027 ≥12% Bridge, Reaffirmed
Management reaffirmed ≥12% adjusted-EPS growth in 2027 off the $25.75 baseline, grounding it in levers already in motion (pricing, care management, portfolio), maturing 2026 investments, and multiple independent drivers rather than any single assumption.
"The path isn't predicated on any single assumption... It's built on many and multiple independent levers, and it's disciplined execution across both health benefits and Carelon." — Gail Boudreaux, CEO
Assessment: The multiple-independent-levers framing is more credible now than at Q4, because two of the levers (Medicaid trough, MA 2027 rate) firmed this quarter and a third (commercial pipeline) strengthened. The base is modest ($25.75), which makes ≥12% off it more achievable.
Analyst Q&A Highlights
The differentiation in cost-trend trajectory across Medicare and Medicaid
An analyst asked management to parse why Medicare trend appears to be moderating while Medicaid remains consistent with recent commentary. Management reframed to the enterprise level — trend tracking in line, no single driver — and emphasized that the outperformance reflects broad execution and self-help actions beginning to show through, not a more benign trend environment it is relying on.
Q: "It seems like you're seeing some level of moderation in Medicare... And then on Medicaid, on the other hand, it seems to be much more consistent... Maybe help us try to understand the differentiation that you're seeing there and what's driving that at this stage."
— Stephen Baxter, Wells Fargo
A: "Cost trend is tracking in line with the expectations... it's not one driver or one single item. What we saw going into this year is solid execution across our entire enterprise... we're not relying on different trend environment to support the guide." — Gail Boudreaux, CEO
Assessment: The "not relying on a better trend environment" framing is the right one for credibility — management is attributing the beat to controllable execution, not a macro tailwind it cannot repeat. That makes the guide more durable, even if it makes the beat sound less exciting.
Medicaid membership mix and embedded acuity pressure
A recurring line of questioning probed whether Medicaid disenrollment is skewing toward lower-utilizing members (pressuring the risk pool) and what acuity assumption sits inside the −1.75% margin. Management confirmed comfort with the high-single-digit membership-decline range (now toward the higher end), characterized timing as modestly favorable, and reiterated the trough call.
Q: "Are you seeing membership declines heavier among lower-utilizing members, potentially pressuring the risk pool? And can you remind us what you've built in for acuity pressure within your Medicaid margin guidance?"
— Justin Lake, Wolfe Research
A: "We remain quite comfortable with our Medicaid membership guidance range... what we've seen to date has been broadly consistent with our expectations. I would say timing has been modestly more favorable than what we originally assumed... this is the trough year." — Mark Kaye, CFO / Gail Boudreaux, CEO
Assessment: Acuity pressure from continued reverification is acknowledged and embedded; "modestly more favorable timing" plus the firm trough reiteration is a constructive read on the segment that matters most. No new negative surprise — itself a win for Medicaid.
How the $935M CMS accrual was derived and how talks are progressing
An analyst asked management to frame how it arrived at the $935M figure and how the CMS conversations are progressing. Management walked through the accrual logic (best estimate of identified probable exposure on historical risk-adjustment policy interpretation), the February notice, the constructive engagement, and the July 31 compliance deadline after which it expects no sanctions.
Q: "I appreciate you sizing the settlement potential CMS. Can you give us a sense on how those conversations are progressing? And... how you arrived at that $935 million figure?"
— Ryan Langston, TD Cowen
A: "The $935 million accrual... reflects our current best estimate of the probable exposure associated with this historical matter... it's not about how we operate the business today... under the current timeline, we have through July 31 to meet all of those compliance requirements... we believe and expect that if we complete those steps that the sanctions will not go into effect." — Gail Boudreaux, CEO
Assessment: The answer was as reassuring as a first-disclosure regulatory item can be — sized, accrued, bounded, and process-defined. The residual is binary (does the July 31 resolution land cleanly), which is why we hold it as a discrete watch item rather than letting it move the rating today.
Decomposing the operating outperformance and its sustainability
An analyst pressed for the breakdown of the beat between durable favorability and one-time/timing items, and whether the better claims management ramps or stays ratable. The CFO's answer produced the cleanest decomposition of the quarter and explicitly protected the 2027 baseline.
Q: "Could you maybe help us parse out the breakdown of that [2/3 favorable claims]?... in terms of some of those better management of claims... Anything we should think about in terms of that ramping up? Or should we think about that as relatively ratable across the rest of 2026?"
— Elizabeth Anderson, Evercore ISI
A: "EPS did come in ahead of our initial outlook, and that included about $0.45 of core outperformance. About 2/3 of that or roughly $0.30 reflected underlying business favorability and the remaining $0.15 was really driven by seasonality-related timing... that dollar [nonrecurring] should clearly be excluded from the 2026 earnings baseline." — Mark Kaye, CFO
Assessment: The granular split — and the proactive baseline carve-out — is the highest-integrity moment of the call. It tells you the durable improvement is modest (~$0.30) and the headline is flattered by one-time items, which is exactly what an analyst needs to model honestly.
Whether stronger ACA enrollment is a risk-pool red flag
A skeptical question invoked the managed-care reflex that better-than-expected exchange enrollment can signal adverse selection, and asked whether the higher ACA membership carries risk-pool deterioration like the 2025 Medicaid-to-exchange migration. Management pointed to early paid-status morbidity data tracking as-priced or better.
Q: "We've been trained to look at better-than-expected enrollment sometimes as a red flag... whether the high enrollment has come with any change in the underlying risk pool that you're seeing?"
— Kevin Fischbeck, Bank of America
A: "Prior claims experience for renewing members in paid status running moderately higher than for the cancel or nonpayment cohorts... that dynamic, that is tracking consistent with or even better than how we price the business in 2026." — Mark Kaye, CFO
Assessment: A direct, data-grounded rebuttal of the adverse-selection fear — the higher morbidity is real but already priced, and the bronze shift is a margin positive. This is the answer that turns ACA from a 2025 liability into a 2026 asset.
The components of the 2027 ≥12% growth and the offset to Medicaid pressure
An analyst asked how to frame the building blocks of the 2027 ≥12% growth — how much rests on controllable pricing/trend, and whether other businesses can offset continued Medicaid pressure. Management reiterated the multiple-independent-levers structure and the maturing-investment step-up.
Q: "Could you help frame how we should be thinking about the components of that 2027 growth... to the degree that Medicaid margins remain pressured next year, how do you feel about the levers and growth opportunities across your other businesses that could offset to drive that at least 12% growth?"
— Jason Cassorla, Guggenheim
A: "The key earnings levers are already in motion... we're making meaningful investments in 2026. So as those investments mature and we realize returns... we're going to see a clear step-up for 2027... the path isn't predicated on any single assumption." — Gail Boudreaux, CEO
Assessment: Management did not lean on Medicaid recovery alone for 2027 — the bridge explicitly survives continued Medicaid pressure via MA, commercial, Carelon, and maturing-investment leverage. With the 2027 MA rate now firmer, that multi-leg structure is more credible than it was at Q4.
What They're NOT Saying
- That the underlying raise was only $0.25. Management led with "at least $26.75" and the $1.25 raise; the modelable improvement to the baseline was a fifth of that. The headline flatters the durable progress.
- Certainty on the CMS sanctions outcome. Management "expects" sanctions won't take effect if it completes the July 31 steps — an expectation, not a guarantee, and the exposure could grow beyond the $935M best estimate.
- An upgraded ACA full-year membership number. Despite tracking to ~1.2M by Q2, management held ≥900K for the year — conservative, but it also signals genuine uncertainty about H2 effectuation and the bronze-cohort cost curve.
- The H2 MLR step-up. The ACA bronze mix defers cost into the back half; Q1's strong margin partly reverses later in the year. It's in the guide, but it wasn't volunteered as a forward headwind.
- How modest the $25.75 baseline is. The 2027 ≥12% sounds powerful, but off a $25.75 base it implies ~$28.85 — still below 2024's $33.04. The recovery restores growth, not the prior peak earnings level, near-term.
Market Reaction
- Pre-print setup: ELV closed at $328.11 on April 21, having rallied 13.4% over the trailing 30 days (off a March low near $289.38) as the recovery thesis gained traction — but still down 6.4% YTD and down 21.1% over the trailing twelve months, within a $275–$429 52-week range.
- Reaction-day move: The stock gapped up 3.0% at the open ($337.88) on the beat-and-raise headline, then faded through the session to close at $328.20, flat (0.0%, +$0.09), on ~1.7x normal volume (3.0M vs. a 1.7M 30-day average). The S&P 500 closed +1.0%, so ELV modestly lagged the tape.
- Where it sits: The $328.20 close leaves ELV at ~12.3x the raised ≥$26.75 guide (~12.7x the clean $25.75 baseline, ~11x a ≥12%-growth 2027) — still a recovery-discount multiple.
The fade-to-flat is the rational reaction to a low-quality beat after a sharp pre-print run. The market correctly discounted the ~$1 nonrecurring gain and the ~$0.15 of ACA timing, recognized the new $935M CMS overhang, and noted that the +13% trailing-month rally had already priced much of the recovery optimism. But "flat after a 13% run, on a nonrecurring-heavy beat, with a fresh regulatory charge" is a constructive non-event, not a thesis-breaker — the durable signals (trough holding, 2027 MA rate firming, baseline ticking up) all moved the right way beneath the muted tape. The stock is consolidating its recovery, not rejecting it.
Street Perspective
Debate: Is the beat-and-raise real progress or a nonrecurring/timing mirage?
Bull view: Strip the optics and the durable signals are unambiguously positive — the clean baseline rose, the benefit ratio beat on self-help, Medicaid is on plan, and the 2027 MA rate firmed; the nonrecurring gain is just gravy on a quarter that confirmed the trajectory.
Bear view: ~80% of the raise and most of the beat are one-time/timing, the underlying improvement is a mere $0.25, and a fresh $935M regulatory charge offsets the good news — this is a quarter dressed up to look better than it operationally was.
Our take: Both are right about the quarter; the bull is right about the thesis. The beat quality is poor, but a beat's composition matters less than whether the recovery's load-bearing pillars strengthened — and they did. The flat reaction already prices the bear's point.
Debate: Does the $935M CMS accrual signal a deeper risk-adjustment problem?
Bull view: It's a sized, accrued, historical matter with a defined CMS process, a July 31 path to no-sanctions, and no bearing on current practices or earnings power — a one-time cash item, not a recurring drag.
Bear view: Risk-adjustment integrity issues have a history of widening once regulators engage; $935M is a "best estimate" that could grow, and sanctions risk — however management frames it — is not fully off the table until July 31.
Our take: We side with the bull on base case and respect the bear on tail risk. The matter is contained and excluded from earnings power, but the July 31 resolution is a discrete, monitorable catalyst; a clean resolution removes an overhang, a messy one would pressure the rating.
Debate: With the recovery confirmed, is the upside priced or still ahead?
Bull view: At ~12x a trough-plus guide with the 2027 MA rate de-risked, the Medicaid trough holding, a near-record commercial pipeline, and a reaffirmed ≥12% 2027 algorithm, the re-rate toward a mid-teens multiple is still largely ahead — the flat reaction is a pause, not a peak.
Bear view: The stock has run 13% into the print and faded; with 2026 still a down year, a fresh CMS charge, and the recovery now consensus, the easy money is made and the multiple may stay range-bound until 2027 earnings actually arrive.
Our take: The risk/reward is less asymmetric than at the Q4 upgrade but still favorable. A ~12x multiple on a recovering, de-risked earnings stream, with multiple confirmed catalysts ahead (July 31 CMS resolution, H2 trough confirmation, 2027 visibility), supports continued ownership — we maintain, rather than add to or trim.
Model Update Needed
| Item | Prior Assumption | Updated | Reason |
|---|---|---|---|
| FY2026 Adjusted EPS | ≥$25.50 | ≥$26.75 (clean base $25.75) | $0.25 underlying + $1.00 nonrecurring |
| FY2026 Medicaid margin | ~−1.75% | ~−1.75% (reaffirmed; Q1 favorable) | Trough holding |
| FY2026 MA margin | ≥2% | ≥2% (on track; 2027 rate firmer) | Portfolio actions + final rate |
| FY2027 Adjusted EPS | ~$28.50+ | ~$28.85+ (≥12% off $25.75) | Higher baseline; MA de-risked |
| One-time CMS charge | — | $935M accrual (excl. adj. EPS) | Historical risk-adjustment matter |
| Buyback | ~$2.3B | ~$2.3B ($1.1B done in Q1 @ ~$300) | Accretive at trough price |
Valuation framework: We hold a fair-value range of roughly $380–$410, equivalent to ~13–14x a ~$28.85 2027 earnings power (≥12% off the $25.75 baseline) — still below ELV's historical mid-teens range, now haircut for the CMS overhang rather than the MA-rate risk that has partly resolved. Against the $328.20 close, the midpoint (~$395) implies ~+20% over our 12-month horizon, before the ~$2.3B buyback and the ~2% dividend. The re-rate path runs through three monitorable checkpoints: the July 31 CMS resolution, H2 confirmation that the Medicaid trough and ACA bronze-cohort costs land as guided, and building 2027 visibility. The thesis no longer needs upside surprises — it needs the de-risked recovery to simply proceed, and Q1 showed it proceeding.
Thesis Scorecard Post-Earnings
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1: The Medicaid trough is real and holds | Confirmed | Q1 slightly favorable; −1.75% reaffirmed; "exactly as anticipated" |
| Bull #2: The 2027 MA rate risk resolves favorably | Confirmed (partial) | CMS final rate firmed above the flat advance notice |
| Bull #3: ACA repositioning works (bronze, morbidity as-priced) | Confirmed | Effectuation ahead; morbidity as-priced; bronze a positive |
| Bull #4: Commercial/Carelon add non-rate legs to 2027 | Confirmed | Near-record 2027 pipeline; CareBridge proof points |
| Bull #5: Clean baseline inflects up | Confirmed | $25.75, first positive revision of the cycle |
| Bear #1: The beat/raise is nonrecurring-heavy | Confirmed (bear) | ~$1 nonrecurring; clean raise only $0.25 |
| Bear #2: New $935M CMS risk-adjustment overhang | Confirmed (bear) | Contained but binary; July 31 resolution to watch |
| Bear #3: Recovery partly priced after a 13% run | Neutral | Flat reaction; re-rate now gradual, not a snap |
Overall: Thesis confirmed and de-risked. The recovery's load-bearing pillars (Medicaid trough, MA 2027 rate) strengthened, the clean baseline inflected up for the first time, and the bridge gained non-rate legs — partly offset by a low-quality beat and a new, contained CMS overhang.
Action: Maintain Outperform. We are past the trough-identification phase (Q4) and into the trough-confirmation phase, which Q1 advanced. We neither add nor trim: the risk/reward remains favorable at ~12x a de-risked, recovering earnings stream, but the nonrecurring-heavy beat, the flat reaction, and the binary CMS resolution argue against chasing. The downgrade triggers are specific: a failed/expanded CMS resolution after July 31, an H2 Medicaid or ACA-bronze cost breakout, or a 2027 setup that stalls the ≥12% algorithm. Absent those, we expect ELV to outperform as the de-risked recovery simply plays out.